14774-56-2

Upstream product

• 1889-77-6 2-bromo-1-(4-methoxy-phenyl)-2-phenyl-ethanone 
• 109-77-3 malononitrile 
• 2700-22-3 Benzylidenemalononitrile 
• 123-11-5 4-methoxy-benzaldehyde 

Downstream Products

• 14774-66-4 6-(4-methoxy-phenyl)-5-phenyl-furo[2,3-d]pyrimidin-4-ylamine 
• 873306-33-3 6-(4-methoxy-phenyl)-5-phenyl-furo[2,3-d]pyrimidin-4-ol 
• 1403893-90-2 C₂₈H₃₂N₄O₂S 
• 1403893-89-9 C₂₆H₂₈N₄O₄ 
• 1415918-73-8 C₂₄H₂₃N₃O₂S 
• 1415918-74-9 C₂₂H₁₉N₃O₄ 
• 1415918-75-0 C₂₃H₂₁N₃O₂S 

Relevant academic research and scientific papers

Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors

Two classes of ACK1 inhibitors, 4,5,6-trisubstituted furo[2,3-d]pyrimidin4- amines and 4,5,6-trisubstituted 7H-pyrrolo[2,3-d]pyrimidin-4-amines, were discovered and evaluated as ACK1 inhibitors. Further structural refinement led to the identification of potent and selective dithiolane inhibitor 37.

An Efficient synthesis of 2-aminofuran-3-carbonitriles via cascade Stetter-γ-ketonitrile cyclization reaction catalyzed by N-heterocyclic carbene

An efficient method for the synthesis of 4,5-disubstituted 2-aminofuran-3-carbonitriles via a cascade Stetter-γ-ketonitrile cyclization reaction of aromatic aldehydes with acylidenemalononitriles, catalyzed by N-heterocyclic carbenes, has been developed.

FURANOPYRIMIDINES

The present invention relates to furanopyrimidine compounds having the general Formula (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula (I), methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula (I).

COMPOUND FOR INHIBITING TYROSINE KINASE ACTIVITY OF DDR2 PROTEIN

A new furopyrimidine compound, their pharmaceutically acceptable salt, and a tyrosine kinase activity inhibitor. The furopyrimidine compound is a compound defined by chemical formula 1, 2, 3 or 4, on their precursor, and can exist as a form of free base or in an acid-addition salt. Since the furopyrimidine compound has an effect of inhibiting activity of DDR2 tyrosine kinase, it can be used in treating illnesses caused by the DDR2 tyrosine kinase activity such as hepatocirrhosis, rheumatoid arthritis or cancer.

Ring Transformation and Reactions of 2-Amino-4,5-dihydrofuran-3,4-dicarbonitriles

The 2-amino-4,5-dihydrofuran-3,4-dicarbonitriles (1a-f) were thermally aromatized to the 2-aminofuran-3-carbonitriles (2a-f) which, in turn, underwent photoxidative ring transformation into the 2,5-dihydro-5-hydroxy-2-oxopyrrole-3-carbonitriles (3b-e).Mil